Lanreotide therapy in a case of thymic neuroendocrine carcinoma associated with syndrome of inappropriate antidiuretic hormone secretion

Paweł Gut; Jakub Fischbach; Daria Baszko-Błaszyk; Marta Fichna; Maria Gryczyńska; Marek Ruchała

doi:10.5114/wo.2011.26447

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2011
vol. 15

Send email

Copy url:

abstract:

Case report

Lanreotide therapy in a case of thymic neuroendocrine carcinoma associated with syndrome of inappropriate antidiuretic hormone secretion

Paweł Gut

,

Jakub Fischbach

,

Daria Baszko-Błaszyk

,

Marta Fichna

,

Maria Gryczyńska

,

Marek Ruchała

Wspolczesna Onkol 2011; 15 (6): 401–404

DOI: https://doi.org/10.5114/wo.2011.26447

Online publish date: 2011/12/28

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Gut P, Fischbach J, Baszko-Błaszyk D, Fichna M, Gryczyńska M, Ruchała M. Lanreotide therapy in a case of thymic neuroendocrine carcinoma associated with syndrome of inappropriate antidiuretic hormone secretion. Contemporary Oncology/Współczesna Onkologia. 2011;15(6):407-410. doi:10.5114/wo.2011.26447.

APA

Gut, P., Fischbach, J., Baszko-Błaszyk, D., Fichna, M., Gryczyńska, M.,  & Ruchała, M. (2011). Lanreotide therapy in a case of thymic neuroendocrine carcinoma associated with syndrome of inappropriate antidiuretic hormone secretion. Contemporary Oncology/Współczesna Onkologia, 15(6), 407-410. https://doi.org/10.5114/wo.2011.26447

Chicago

Gut, Paweł, Jakub Fischbach, Daria Baszko-Błaszyk, Marta Fichna, Maria Gryczyńska,  and Marek Ruchała. 2011. "Lanreotide therapy in a case of thymic neuroendocrine carcinoma associated with syndrome of inappropriate antidiuretic hormone secretion". Contemporary Oncology/Współczesna Onkologia 15 (6): 407-410. doi:10.5114/wo.2011.26447.

Harvard

Gut, P., Fischbach, J., Baszko-Błaszyk, D., Fichna, M., Gryczyńska, M.,  and Ruchała, M. (2011). Lanreotide therapy in a case of thymic neuroendocrine carcinoma associated with syndrome of inappropriate antidiuretic hormone secretion. Contemporary Oncology/Współczesna Onkologia, 15(6), pp.407-410. https://doi.org/10.5114/wo.2011.26447

MLA

Gut, Paweł et al. "Lanreotide therapy in a case of thymic neuroendocrine carcinoma associated with syndrome of inappropriate antidiuretic hormone secretion." Contemporary Oncology/Współczesna Onkologia, vol. 15, no. 6, 2011, pp. 407-410. doi:10.5114/wo.2011.26447.

Vancouver

Gut P, Fischbach J, Baszko-Błaszyk D, Fichna M, Gryczyńska M, Ruchała M. Lanreotide therapy in a case of thymic neuroendocrine carcinoma associated with syndrome of inappropriate antidiuretic hormone secretion. Contemporary Oncology/Współczesna Onkologia. 2011;15(6):407-410. doi:10.5114/wo.2011.26447.

PlumX metrics:

Neuroendocrine tumours of the thymus are rare neoplasms, which account for 2-4% of all anterior mediastinal tumours. Several endocrinopathies were found to be associated with these tumours, with ectopic ACTH secretion reported most frequently. Here we provide a description of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) accompanying neuroendocrine thymic carcinoma. A mediastinal tumour was incidentally found on routine chest X-ray examination in a 55-year-old man. After detailed imaging studies, tumour excision was performed. The mediastinal tumour (11  8  4 cm) presented features of invasion to the left lung and pericardium. Histopathological examination confirmed the diagnosis of thymic neuroendocrine carcinoma. The patient was treated with chemotherapy because of the recurrence. Symptoms of carcinoid syndrome and positive result of the somatostatin receptor scintigraphy justified subsequent introduction of somatostatin analogue therapy. At this point low serum sodium levels accompanied by decreased serum osmolarity and inadequate urine concentration were found. Having excluded other typical causes, SIADH syndrome due to ectopic vasopressin synthesis was assumed. This finding adds to differential diagnosis of hyponatraemia, indicating that SIADH may also accompany thymic neuroendocrine tumours.

keywords:

Lanreotide therapy in a case of thymic neuroendocrine carcinoma associated with syndrome of inappropriate antidiuretic hormone secretion

Paweł Gut , Jakub Fischbach , Daria Baszko-Błaszyk , Marta Fichna , Maria Gryczyńska , Marek Ruchała

neuroendocrine tumour, thymus, SIADH, lanreotide

Paweł Gut

,

Jakub Fischbach

,

Daria Baszko-Błaszyk

,

Marta Fichna

,

Maria Gryczyńska

,

Marek Ruchała